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Abstract: Strokes are one of the leading causes of mortality and chronic morbidity in the world, yet
with only limited successful interventions available at present. Our previous studies revealed the
potential role of the glucocorticoid receptor (GR) in the pathogenesis of neonatal hypoxic-ischemic
encephalopathy (HIE). In the present study, we investigate the effect of GR knockdown on acute
ischemic brain injuries in a model of focal cerebral ischemia induced by middle cerebral artery
occlusion (MCAO) in adult male CD1 mice. GR siRNAs and the negative control were administered
via intracerebroventricular (i.c.v.) injection 48 h prior to MCAO. The cerebral infarction volume
and neurobehavioral deficits were determined 48 h after MCAO. RT-qPCR was employed to assess
the inflammation-related gene expression profiles in the brain before and after MCAO. Western
Blotting was used to evaluate the expression levels of GR, the mineralocorticoid receptor (MR)
and the brain-derived neurotrophic factor/tropomyosin receptor kinase B (BDNF/TrkB) signaling.
The siRNAs treatment decreased GR, but not MR, protein expression, and significantly enhanced
expression levels of pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α) in the brain. Of interest,
GR knockdown suppressed BDNF/TrkB signaling in adult mice brains. Importantly, GR siRNA
pretreatment significantly increased the infarction size and exacerbated the neurobehavioral deficits
induced by MCAO in comparison to the control group. Thus, the present study demonstrates the
important role of GR in the regulation of the inflammatory responses and neurotrophic BDNF/TrkB
signaling pathway in acute ischemic brain injuries in adult mice, revealing a new insight into the
pathogenesis and therapeutic potential in acute ischemic strokes.
Keywords: GR; MR; GR siRNA; ischemic stroke; MCAO; inflammation; BDNF/TrkB
1. Introduction
Strokes rank as the fifth cause of mortality and the leading cause of major disability in the United
States [1,2]. Approximately about 795,000 stroke events occur in the United States annually, of which
more than 80% cases are ischemic attacks [1]. Every 4 min, someone will die from a stroke attack [1].
The total direct medical stroke-related costs were approximately $71.6 billion in 2012 and such costs
will be tripled to $184.1 billion in 2030 [1,3]. However, the available clinically practicable interventions
are still very limited after decades of practice and investigation, which is at least in part attributable
to the incomplete understanding of its basic pathogenesis. Therefore, it is urgent to further explore
the potential mechanisms underpinning acute stroke events and to develop feasible and effective
intervention strategies.
Int. J. Mol. Sci. 2018, 19, 2428; doi:10.3390/ijms19082428 www.mdpi.com/journal/ijms
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Growing evidence has shown the critical role of glucocorticoids in the brain’s growth and
development. Endogenous or exogenous glucocorticoids exert significant effects on the brain’s
activities in various physiological and pathological conditions chiefly via the activation of the
glucocorticoid receptor (GR) [4]. Aberrant GR activity is implicated in diverse brain pathologies [4].
Our previous studies revealed that GR activation in the developing rat brain confers neuroprotective
effects in the model of neonatal HIE [5,6]. In addition, maternal hypoxia induced the down-regulation
of GR in immature brain programs an ischemic-sensitive phenotype in neonatal rat pups [7]. However,
the role of GR signaling in the fully developed and mature brain with ischemic challenges is still vague
and needs to be further elucidated.
In the present study, we explored the potential role of GR in the setting of acute ischemic
brain injuries with a classic middle cerebral artery occlusion (MCAO) model in adult mice. Herein,
we present evidence that the repression of basal GR in the adult mouse brain induces heightened
pro-inflammatory responses and suppresses neurotrophic BDNF/TrkB signaling, which contributes
to an enhanced infarct size and worsened neurobehavioral deficits induced by MCAO insult. The
findings provide new insights into a potential intervention strategy of targeting GR in the management
of acute ischemic stroke events in clinics.
2. Results
2.1. GR siRNA Treatment Repressed GR Expression in the Brain
GR siRNAs (100 pmol) were administered via i.c.v. injection, and GR protein expression in the
brain was determined 48 h after the treatment. As demonstrated in Figure 1A, GR siRNA treatment
significantly down-regulated GR protein abundance in the mouse brain at 48 h after injection, whilst no
marked effects at 24 h. Given the potentially complex balance effect of GR and MR in the brain [8–12],
we also investigated the possible effects of GR down-regulation on the expression level of MR. Western
blotting indicated that MR protein abundance in the brain was not significantly altered by the GR
siRNA treatment (Figure 1B).
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Figure 1. The glucocorticoid receptor (GR) siRNA repressed GR expression in mice brain. The mice received
either GR siRNA (100 pmol) or its negative control (Neg. Control; 100 pmol) via intracerebroventricular
(i.c.v.) injection. The brain samples were collected at 24 h and 48 h after i.c.v. treatment. Glucocorticoid
receptor (GR) protein abundance (A) and mineralocorticoid receptor (MR) protein abundance (B) were
determined via western blotting at 24 h and 48 h, respectively. n = 5. * p < 0.05, GR siRNA vs Control.
Int. J. Mol. Sci. 2018, 19, 2428 3 of 13
2.2. GR Repression Induced Heightened Inflammatory Responses in the Mouse Brain
Given the pivotal role of GR in the modulation of inflammatory responses, we examined the
expression profiles of key inflammation-related genes in the mouse brain via RT-qPCR. As shown in
Figure 2, the GR knockdown by GR siRNAs markedly increased expression levels of pro-inflammatory
cytokines, including IL-6, IL-1β, and TNF-α (Figure 2A–C), suggesting a potential role of endogenous
glucocorticoids activating the GR and repressing pro-inflammatory response in the mouse brain. Of
interest, GR knockdown did not exert effects on expression levels of anti-inflammatory genes—IL-10
and TGF-β (Figure 2E,F)—and inflammatory chemokines—CCL2 and CCL3 (Figure 2G,H).
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Figure 2. The GR repression increased expression of pro-inflammatory genes in mice brains before 
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Figure 2. The GR repression increased expression of pro-inflammatory genes in mice brains before
MCAO treat ent. The mice received either GR siRNA (100 pmol) or its negative control (Neg. Control;
100 pmol) via in racerebroventricular (i.c.v.) injection. The brain samples were collected at 48 h after
i.c.v. injection. No middle cerebral artery occlusion (MCAO) was conducted. Quantitative reverse
transcription polymerase chain reaction (RT-qPCR) was utilized to assess inflammation-related genes
expression profiles, including IL-6 (A), LI-1β (B), TNF-α (C), IFN-γ (D), IL-10 (E), TGF-β (F), CCL2 (G)
and CCL3 (H), respectively. n = 5. * p < 0.05, GR siRNA vs. Neg. Control.
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We further assessed the expression profiles of inflammation-related genes in adult mice brains
subjected to the MCAO challenge. As shown in Figure 3, the MCAO challenge itself induced a
significant up-regulation of pro- and anti-inflammatory genes in the brains of both control and
treatment animals, including IL-6, IL-1β, TNF-α, IL-10, CCL2, and CCL3 (Figure 3A–C,E,G,H),
indicating a pivotal role of neuroinflammation in the pathology of acute ischemic stroke events.
Interestingly, MCAO insult induced a significant increase in IFN-γ and TGF-β only in the GR siRNA
treated animals (Figure 3D,F). Of importance, in comparison to the control group, the GR siRNA
treated animals demonstrated much higher increased levels of pro-inflammatory genes, IL-6, IL-1β,
and TNF-α (Figure 3A–C), at 12 h after the MCAO induction, which is consistent with the profile
patterns without MCAO insult. We also observed a significant increase in the IL-10 and CCL3 genes in
GR siRNA treated mice brain compared with the controls (Figure 3E,H).
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Figure 3. The GR repression induced heightened inflammatory responses in mice brains following 
MCAO. The mice received either GR siRNA (100 pmol) or its negative control (Neg. Control; 100 
Figure 3. The GR repression induced heightened inflammatory responses in mice brains following
MCAO. The mice received either GR siRNA (100 pmol) or its negative control (Neg. Control; 100 pmol)
via intracerebroventricular (i.c.v.) injection. A middle cerebral artery occlusion (MCAO) was performed
48 h after i.c.v. injection. Sham animals were subjected to left internal carotid artery exposure
but without suture insertion. The brain samples were collected at 12 h after MCAO induction.
A quantitative reverse transcription polymerase chain reaction (RT-qPCR) was utilized to assess
inflammation-related genes expression profiles, including IL-6 (A), LI-1β (B), TNF-α (C), IFN-γ (D),
IL-10 (E), TGF-β (F), CCL2 (G) and CCL3 (H), respectively. n = 5. * p < 0.05, MCAO vs. sham; # p <
0.05, GR siRNA vs. Neg. Control.
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2.3. GR Repression Suppressed BDNF/TrkB Signaling in Mice Brains
The neurotrophic effect of BDNF/TrkB signaling is well recognized in a diverse brain physiology
and pathology [13–15]. We explored a potential role of GR repression in the regulation of BDNF/TrkB
signaling in adult mouse brains. We found that the GR repression with GR siRNA treatment
significantly decreased the TrkB and mature-BDNF protein abundance in the brain (Figure 4B),
suggesting a potential interaction between the GR and BDNF/TrkB signaling in adult mouse brains.
GR siRNA treatment also induced a transient decrease of the pre-BDNF level at 24 h, which was
restored at 48 h (Figure 4A,B).
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Figure 4. The GR repression inhibited brain-derived neurotrophic factor/tropomyosin receptor kinase
B (BDNF/TrkB) signaling in mice brains. The mice received either GR siRNA (100 pmol) or its negative
control (Neg. Control; 100 pmol) via intracerebroventricular (i.c.v.) injection. The brain samples were
collected at 24 h and 48 h after i.c.v. treatment. The brain-derived neurotrophic factor (BDNF; pre- and
mature-BDNF) and Tropomyosin receptor kinase B (TrkB) were determined via western blotting at
24 h (A) and 48 h (B), respectively. n = 5. * p < 0.05, GR siRNA vs. Control.
2.4. GR Repression Increased Infarction Size and Worsened Neurobehavioral Deficits in MCAO Insult
Compared to control animals, MCAO induced significantly increased infarction size in the brain
of GR siRNA pretreated mice (25.16% ± 11.69% vs. 15.96% ± 6.85%; Figure 5A). Of importance, GR
siRNA treated animals presented with a much worse performance in neurobehavioral tests as shown in
a decrease in neurological scores (8.88 ± 2.29 vs. 12.75 ± 3.05; Figure 5B) and an increase in percentage
values in foot fault test (56.00% ± 5.57% vs. 33.88% ± 4.47%; Figure 5C), suggesting that GR repression
in the brain also exacerbates functional outcomes in acute ischemic strokes.
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Figure 5. The GR repression increased the infarction size and worsened neurobehavioral deficits in
mice with MCAO. The mice received either GR siRNA (100 pmol) or its negative control (Neg. Control;
100 pmol) via intracerebroventricular (i.c.v.) injection. A middle cerebral artery occlusion (MCAO) was
performed 48 h after i.c.v. injection. The brain infarction size was assessed 48 h after MCAO conduction
(A). Neurobehavioral tests including Neurological Score (B) and Foot Fault (C) were evaluated before
MCAO conduction and 48 h after MCAO conduction, respectively. n = 10–12. * p < 0.05, pre-MCAO vs.
post-MCAO; # p < 0.05, GR siRNA vs. Control. Scale bar, 2 mm.
3. Discussion
The present study demonstrated several novel findings: 1. The repression of GR in adult
mouse brains induced an enhanced inflammatory response in the context of both physiological
and pathological conditions; 2. GR down-regulation inhibited the activity of neurotrophic BDNF/TrkB
signaling in adult brains; 3. Of importance, GR repression sensitized the brain to acute ischemic insult,
leading to an increased infarct size and worsened neurobehavioral performance in MCAO challenge.
Taken together, our present study further revealed a potential role of GR in the homeostasis and
pathology of a fully-developed brain.
It is well recognized that the brain is one of the major targets of glucocorticoids [4,5]. Chiefly via
the activation of GR, glucocorticoids affect various physiological and pathological processes in the
brain, which may be neurodegenerative or neuroprotective, depending on experimental protocols,
dosage, time, animal age, strains, and species [4,5,16–22]. The mineralocorticoid receptor (MR) is
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another adrenal steroid receptor. GR and MR have different affinities to glucocorticoids, of which
MR presents a relatively high affinity and is highly bound at basal levels of glucocorticoids, whilst
GR binds glucocorticoids weakly at physiological levels [12]. MR is close to saturation with low
basal concentrations of corticosterone, while high corticosterone concentrations in stressful events
occupy both MR and GR [12]. MR is mainly found in the limbic areas, particularly the hippocampus,
while GR is more widely distributed in all brain regions [12,23]. The dysregulation of MR/GR
balance is implicated in various neuropathological conditions [8–10]. The potential effect of MR in
the regulation of brain ischemic injury has been suggested [6,24,25]. In the present study, we found
that the knockdown of GR via GR siRNA i.c.v. exerted no significant influence on MR, providing a
model to elucidate the specific effects of GR repression in the pathogenesis of brain ischemia without
the compounding influence of MR.
Inflammation is one of the major pathological processes underpinning various neurodegenerative
diseases [26]. At the acute stage of strokes, a vast amount of toxic inflammatory factors secreted
by activated brain resided or peripherally infiltrated immune cells synergistically contribute to the
irreversible cell death and infarction formation [2,27]. In the present study, we observed a robust
up-regulation of various pro- and anti-inflammatory genes, such as IL-6, IL-1β, TNF-α, IL-10, CCL2,
and CCL3, in the mouse brain subjected to the MCAO challenge. Of interest, even without an
MCAO insult, GR siRNA treated animals demonstrated a significant increase in key pro-inflammatory
genes, IL-6, IL-1β, TNF-α, in the brain, indicating that the GR repression impaired normally negative
regulation of GR on pro-inflammatory genes and primed the brain in a pre-inflammatory state. This is
consistent with the well-documented anti-inflammatory effects of GR [24,28,29]. Of critical importance,
GR repression in the brain significantly heightened the inflammatory response induced by the MCAO
challenge. There were much higher expression levels of pro-inflammatory factors at 12 h after MCAO in
the brains of GR siRNA treated mice compared to the control animals. It is possible that this enhanced
inflammatory response sensitizes the brain to the ischemic injury, leading to exacerbated neurological
outcomes. Interestingly, the GR siRNA treatment also induced an increase in anti-inflammatory
cytokine IL-10 levels after MCAO induction, which may be a compensatory protective response. In
the present study, GR repression did not exert effects on the expression of IFN-γ, TGF-β, and CCL2,
suggesting its complicated differential regulation effects on inflammation-related factors in adult
mouse brains.
Another novel finding of our study is that basal GR repression significantly inhibited neurotrophic
BDNF/TrkB signaling in the brain. BDNF is a member of the neurotrophic family, which promotes
neuronal survival, axonal growth, and neuroprotection, and has been recognized as a potential
therapeutic agent for different neurodegenerative diseases [30–32]. BDNF exerts neuroprotective
effects mainly via binding to its high-affinity tropomyosin-receptor kinase B (TrkB) [33,34]. In the
present study, accompanied with the down-regulation of basal GR protein, there was a significant
decrease of both TrkB and the mature-BDNF protein abundance in the brain, as well as a transient
down-regulation of pre-BDNF. These findings indicate that GR repression disturbs the expression
pattern of BDNF/TrkB, implying a possible linkage between glucocorticoid-GR signaling and the
BDNF/TrkB pathway in the mature brain. Indeed, although lacking in detailed descriptions, a
few studies began to report the possible linkage of these two vital signaling pathways in the brain.
Alboni and colleagues showed that under the basal condition, mice with impaired GR expression
displayed lower levels of BDNF exons IX and IV and decreased CRE(BDNF) binding activity with
respect to wild-type (WT) mice in the hippocampus [35]. Pandya and colleagues also reported that
acute corticosterone exposure induced an increase in the TrkB proteins levels in primary cortical
neurons, which was GR-dependent [36]. Jeanneteau and colleagues demonstrated that dexamethasone
promoted TrkB receptor phosphorylation in rat brains and offered neuroprotective effects [15]. Chen
and colleagues recently speculated that the GR was upstream of TrkB phosphorylation and the
activation of BDNF-mediated signaling [37]. Consistently, our present study also demonstrated
that the repression of basal GR inhibited the activities of BDNF/TrkB signaling, providing further
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evidence of the cross-talk between GR and BDNF/TrkB in the adult brain. Given its well-documented
neurotrophic effects, it is likely that the GR repression mediated inhibition of BDNF/TrkB also plays
an important role in the enhanced susceptibility to acute cerebral ischemic injury induced by MCAO
as observed in the present study. One of our recent studies also revealed that perinatal nicotine
exposure induced the down-regulation of BDNF/TrkB, which resulted in an increased infarction size
in neonatal rat brain hypoxic and ischemic injuries [38]. Both glucocorticoid-GR and BDNF/TrkB play
critical roles in the brain’s physiology and pathology, their potential cross-talk linkages are warranted
further exploration.
Consistent with our previous studies in neonatal rat brains, the present study revealed the
protective effect of GR in adult mouse brain in response to acute ischemic injury. Our previous studies
demonstrated that pre- and post-glucocorticoid treatment conferred neuroprotection in neonatal HIE
via GR activation, while maternal hypoxia induced the inhibition of GR programs an ischemic sensitive
phenotype in neonatal rat brain [5–7,39]. In the present study, we administered the siRNA technique
to knockdown local basal GR protein levels in the brain, and employed an adult mice MCAO model to
investigate the causal role of GR in acute cerebral ischemia in the fully developed brain. As presented
in our study, GR siRNA treated mice showed significantly enhanced infarction sizes and exacerbated
neurobehavioral deficits compared with the control animals, which was chiefly attributable to the
heightened inflammatory responses and suppression of neurotrophic BDNF/TrkB signaling induced
by GR repression. Thus, the present finding provides further evidence that GR serves as a common
pivotal component implicated in severe ischemic cerebral injuries in both developing and developed
brains, suggesting a promising molecular intervention target in the setting of acute ischemic strokes in
the adult.
Several limitations deserve to be mentioned. Our present study evaluated the negative impacts
of GR repression on acute ischemic brain injury. Given that chronic functional deficits are a major
disability sequela of stroke, additional studies are needed to explore the roles of GR in the long-term
functional outcomes in the future. Although we revealed that GR repression induced heightened
inflammatory responses and suppressed BDNF/TrkB in adult mouse brains, the detailed underlying
molecular mechanisms remain to be determined. In addition, the potential linkage between the
suppressed BDNF/TrkB and heightened inflammatory responses induced by GR repression is another
exciting puzzle warranted to be further investigated. Of importance, pre-clinical studies should be
performed to assess the potential protective effects of GR activation in adult ischemic brain injuries.
4. Materials and Methods
4.1. Experimental Animals
A total of 72 eight-week-old male CD1 mice were purchased from Charles River Laboratories
(Portage, MI). The animals were maintained at 20 ± 2 ◦C and housed in a 12-h light-dark cycle with
access to food and water ad libitum. The mice were randomly divided into 2 major groups and
several subgroups. The two major groups included (1) negative control (n = 35); and (2) GR siRNA
administered via intracerebroventricular injection (i.c.v) (n = 37). Experimental subgroups were listed
as followed: Group 1: Western blotting analysis of protein abundance (n = 5 in each group at 24 h and
48 h after i.c.v. treatment, respectively); Group 2: quantitative real-time PCR of inflammation-related
genes (n = 5 in each group at 48 h after i.c.v. treatment and 12 h post-MCAO, respectively); Group 3:
infarction and neurobehavioral function assays (n = 10 in negative control, n = 12 in the GR siRNA
treatment). All the experimental procedures and protocols (IACUC# 8160017, approved on 22 July
2016) were approved by the Institutional Animal Care and Use Committee of Loma Linda University
and followed the guidelines by the National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
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4.2. Middle Cerebral Artery Occlusion (MCAO)
Focal cerebral ischemia was induced by intraluminal middle cerebral artery occlusion (MCAO)
as described previously [2,40]. Briefly, mice were anesthetized with isoflurane (5% for induction and
2% for maintenance) using a face mask. The left common carotid artery and external carotid artery
were exposed through a midline neck incision. A 6-0 nylon monofilament coated with silicon rubber
(Doccol) was introduced into the left internal carotid artery through the external carotid stump to
occlude the origin of the middle cerebral artery and block blood flow to the striatum and cortex. After
50 min of occlusion, reperfusion was introduced by filament withdrawal, and the incision was sutured.
During the whole procedure, the mice body temperature was maintained at 37 ± 0.5 ◦C. No animal
died during the MCAO procedure. The mortality of the follow-up study was 10% in the negative
control group and 12% in the GR siRNA treatment group. In total, 81 mice were used in this study.
4.3. Intracerebroventricular Injection (i.c.v)
As previously described [2], the adult male CD1 mice were anesthetized with isoflurane (5%
for induction and 2% for maintenance) and placed in a stereotaxic frame (Stoelting Co., Wood Dale,
Illinois, IL, USA). The ocular ointment was applied to the eyes to prevent drying, animal heads were
wiped with 70% ethanol, and the skin on the head was cut open along the midline. A small burr
hole (0.5 mm diameter, F.S.T.) was drilled into the skull (0.3 mm posterior to bregma; 1.0 mm lateral
to sagittal suture). GR siRNA (Dharmacon) and the negative control (Dharmacon), were prepared
according to the manufacturer’s instructions. Total 100 pmol GR siRNA or the negative control with a
total volume of 4 µL, were injected over a 5-min period into the left lateral ventricle (depth: 3.0 mm
dorsal) with a 10 µL syringe (Stoelting, Wood Dale, Illinois, IL, USA). The wound was closed with a
suture, and the mice were waiting to wake up on a heating pad.
4.4. Measurement of Infarction Size
The mice were euthanized 48 h after the MCAO treatment. Coronal slices of the brain (2 mm
thick) were cut and immersed in a pre-warmed, 2% solution of 2,3,5-triphenyltetrazolium chloride
monohydrate for 10 min at 37 ◦C followed by fixation with 10% formaldehyde overnight [41]. Both
sides of each slice were photographed separately. The infarction area was analyzed by the Image J
software (Version 1.40; National Institutes of Health, Bethesda, Maryland, MD, USA), summed for
each brain, and expressed as a percentage of the whole brain.
4.5. Neurobehavioral Tests
The neurological score test and foot-fault test were utilized to evaluate the functional neurological
deficits. Both tests were conducted before and 48 h after MCAO by an observer blinded to the
experimental groups. In total, six components constitute the neurological score test, including
spontaneous activity, symmetry in the movement of limbs, forepaw outstretching, climbing, body
proprioception, and response to vibrissae touch [2,42]. The final score for each animal is the summation
of all six individual trial scores. The minimum score is 3 and the maximum is 18. Lower scores
represent more severe functional deficits. The foot-fault test assesses the forelimb misplacement on
a grid during locomotion. For each animal, the total number of steps and the number of times each
forelimb fell below the grid during the performance of 5 min or during a total of 50 steps achieved
with one forelimb were recorded, and the percentage of the right forelimb (affected by stroke) foot fault
to the total steps was calculated [2,43]. In contrast to the neurological score test, higher percentage
values represent more severe deficits. Both tests were videotaped and analyzed by an observer blinded
to the experimental groups.
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4.6. Western Blotting
Protein abundance was determined by western blotting as previously described [39]. Briefly, the
animals were euthanized at the scheduled time point and brain samples were isolated. The brain
tissues (left half brain) were homogenized in a radioimmunoprecipitation assay (RIPA) lysis buffer
(Santa Cruz Biotechnology, Dallas, Texas, TX, USA) followed by further centrifugation at 4 ◦C for
20 min at 14,000 g, and the supernatants were collected. Then the samples with equal amounts of
protein were loaded onto 10% polyacrylamide gel with 0.1% sodium dodecyl sulfate and separated
by electrophoresis at 100 V for 120 min. The proteins were then transferred onto nitrocellulose
membranes and probed with primary antibodies against GR (1:1000, Cell Signaling Technology,
Danvers, MA), MR (1:500, Abcam, Cambridge, Massachusetts, MA, USA), BDNF (1:1000, Santa
Cruz Biotechnology, Santa Cruz, California, CA, USA), and TrkB (1:1000, Santa Cruz Biotechnology,
Santa Cruz, California, CA, USA), respectively. After washing, the membranes were incubated with
secondary horseradish peroxidase-conjugated antibodies. The proteins were visualized with enhanced
chemiluminescence reagents, and blots were exposed to Hyperfilm. The results were quantified
with the Kodak electrophoresis analysis system and Kodak ID image analysis software (Kodak,
Rochester, New York, NY, USA). The target protein abundance was normalized to the abundance of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a protein loading control.
4.7. Real-time RT-PCR
As previously described [2], the total RNA (left half brain) was extracted using the TRIzol
reagent (Invitrogen) and subjected to reverse transcription with Superscript III First-Strand Synthesis
System (Invitrogen), following the manufacturer’s instructions. The target gene mRNA abundance
was determined by real-time PCR using SYBR Green Supermix (Biomake). Real-time RT-PCR was
performed in a final volume of 25 µL. The PCR reaction conditions were a 5-min hold at 95 ◦C,
followed by 40 cycles of activation for 15 s at 95 ◦C and annealing/extending for 60 s at 60 ◦C. The
detected target gene primers were listed as the following: IL-6, 5′-ccacggccttccctacttc-3′(forward) and
5′-tgggagtggtatcctctgtgaa-3′(backward); IL-1β, 5′-gagtgtggatcccaagcaat-3′(forward) and 5′-taccagttg
gggaactctgc-3′(backward); TNF-α, 5′-cagccgatgggttgtacctt-3′(forward) and 5′-ggcagccttgtcccttg
a-3′(backward); IFN-γ, 5′-tgctgatgggaggagatgtct-3′(forward) and 5′-tgctgtctggcctgctgtta-3′(backward);
IL-10, 5′-gatgccccaggcagagaa-3′(forward) and 5′-cacccagggaattcaaatgc-3′(backward); TGF-β, 5′-ccgc
ttctgctcccactc-3′(forward) and 5′-ggtacctccccctggctt-3′(backward); CCL2, 5′-aggtgtcccaaagaagctgtag-3′
(forward) and 5′-aatgtatgtctggacccattcc-3′(backward); and CCL3, 5′-tggaactgaatgcctgagagt-3′(forward)
and 5′-taggagatggagctatgcaggt-3′(backward). The PCR reactions were carried out in triplicate, and
threshold cycle numbers were averaged for each sample. The Ct values were normalized relative to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
4.8. Statistical Analysis
The data are expressed as mean ± standard deviation (SD). D’Agostino-Pearson omnibus test
and Shapiro–Wilk test were used for normality test. The data were assessed by one way analysis of
variance (ANOVA) followed by Neuman-Keuls post-hoc testing for comparisons of multiple groups or
Student’s t-test (unpaired, two-tailed) for comparisons between two groups, where appropriate, using
the Graph-Pad Prism software (GraphPad Software Version 4, San Diego, California, CA, USA). For all
comparisons, p < 0.05 indicated statistical significance.
5. Conclusions
The present study revealed the vital role of GR in the regulation of inflammation in the adult brain.
Inhibition of basal GR induces heightened inflammatory responses and suppression of neurotrophic
BDNF/TrkB signaling, resulting in an increased susceptibility to acute ischemic brain injury. GR is
an essential component in maintenance of brain homeostasis. Aberrant GR activity is implicated
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in various complex brain pathologies, including acute cerebral ischemia. The findings provide a
new insight into the understanding of pathogenesis in ischemic brain injury, and suggest a possible
intervention target in the setting of acute ischemic stroke in the adult.
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